Results 191 to 200 of about 49,705 (278)

Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans

open access: yesJournal of the Peripheral Nervous System, Volume 31, Issue 1, March 2026.
ABSTRACT Background and Aims Bortezomib‐induced peripheral neuropathy (BIPN) remains a common treatment side effect in patients with multiple myeloma (MM). Data from rodent models indicate a role of proinflammatory cytokines in BIPN pathophysiology, making them potential therapeutic targets.
Nadine Cebulla   +18 more
wiley   +1 more source

Inequalities in availability of clinical trials for pediatric, adolescent, and young adult patients with cancer in Europe: results from the SIOPE OCEAN project. [PDF]

open access: yesLancet Reg Health Eur
Rauwolf KK   +14 more
europepmc   +1 more source

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Hereditary Transthyretin Amyloidosis Polyneuropathy

open access: yesJournal of the Peripheral Nervous System, Volume 31, Issue 1, March 2026.
ABSTRACT Background and Aims In individuals with hereditary transthyretin amyloidosis (ATTRv) polyneuropathy, monitoring of disease progression and treatment response is crucial. The objective is to determine if serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) are reliable biomarkers of ATTRv polyneuropathy ...
Valentin Loser   +9 more
wiley   +1 more source

Understanding Nurses' and Physicians' Knowledge, Use and Perspectives on Nitrous Oxide/Oxygen Use in Paediatrics: A Cross‐Sectional Study

open access: yesNursing in Critical Care, Volume 31, Issue 2, March 2026.
ABSTRACT Background Nitrous oxide/oxygen (N2O/O2 50%/50%) is an effective and safe technique for procedural sedation in paediatric settings; however, the knowledge, use and perspectives of healthcare professionals regarding N2O/O2 remain limited. Aim To investigate the knowledge, use and perspectives of healthcare professionals regarding N2O/O2 in ...
Valentina Simonetti   +9 more
wiley   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 2, Page 310-323, February 2026.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini   +13 more
wiley   +1 more source

Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML‐M4 and AML‐M5, Treated With Venetoclax Plus Azacitidine

open access: yes
American Journal of Hematology, Volume 101, Issue 3, Page 577-580, March 2026.
Marina Konopleva   +8 more
wiley   +1 more source

A set of serum proteomic biomarkers differentiates celiac children from age and human leukocyte antigen‐matched healthy controls

open access: yesJournal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 2, Page 508-515, February 2026.
Abstract Objective The latest European Society of Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria for celiac disease (CD) diagnosis reduced the requirement for a small intestinal biopsy but still, for most of the cases a small intestinal biopsy is required for a safe diagnosis: hence the attempt to identify serum biomarkers that could ...
Roberta Mandile   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy